转移性结直肠癌第二次疾病进展后的治疗:TRIBE与TRIBE2研究的汇总分析
该汇总分析纳入TRIBE和TRIBE2两项随机III期研究中的1187例转移性结直肠癌患者,评估第二次疾病进展后各线治疗的衰减率、治疗选择及临床结局。结果显示,625例(53%)、326例(27%)和136例(11%)患者分别在第二、三、四次疾病进展后接受了系统治疗;RAS/BRAF野生型患者接受三线治疗的比例为75%,高于RAS突变型(66%,p=0.005)和BRAF突变型(66%,p=0.11)。三线治疗中,67%的RAS/BRAF野生型患者接受抗EGFR治疗,其PFS为6.4个月,优于其他治疗的3.9个月(p=0.02)。
要点
- 第二次疾病进展后仅53%患者接受系统治疗,第三次后27%,第四次后11%。
- RAS/BRAF野生型患者三线治疗接受率为75%,高于RAS突变型66%(p=0.005)和BRAF突变型66%(p=0.11)。
- RAS/BRAF野生型患者三线抗EGFR治疗PFS 6.4个月,优于其他治疗3.9个月(p=0.02)。
核心结论
- 各线治疗间存在明显的衰减率,在RAS和BRAF突变患者中更为显著,凸显了一线治疗选择的重要性。
- 在未接受过抗EGFR治疗的RAS/BRAF野生型患者中,抗EGFR药物的疗效高于其他选择。
- 化疗再引入在临床实践中仍然频繁。
研究设计与样本
- 对TRIBE和TRIBE2两项随机III期研究中1187例转移性结直肠癌患者进行的汇总分析,一线比较FOLFOXIRI/贝伐珠单抗与FOLFOX或FOLFIRI/贝伐珠单抗。
- 评估每线治疗的衰减率、治疗选择及临床结局。
主要发现
- 625例(53%)、326例(27%)和136例(11%)患者分别在第二、三、四次疾病进展后接受了系统治疗。
- PFS和客观缓解率随每线治疗递减。
- RAS/BRAF野生型患者接受三线治疗的比例为75%,高于RAS突变型(66%,p=0.005)和BRAF突变型(66%,p=0.11)。
- 三线治疗中,67%的RAS/BRAF野生型患者接受抗EGFR治疗,其PFS为6.4个月,优于其他治疗的3.9个月(p=0.02)。
- TRIBE患者三线OS呈现更长趋势(9.9个月 vs 7.2个月,p=0.05)。
关键数值与推荐
- 衰减率:第二次疾病进展后53%,第三次后27%,第四次后11%。
- RAS/BRAF野生型 vs RAS突变型三线治疗接受率:75% vs 66%(p=0.005)。
- RAS/BRAF野生型 vs BRAF突变型三线治疗接受率:75% vs 66%(p=0.11)。
- RAS/BRAF野生型患者三线抗EGFR治疗 vs 其他治疗PFS:6.4个月 vs 3.9个月(p=0.02)。
- TRIBE vs 对照三线OS:9.9个月 vs 7.2个月(p=0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The availability of new drugs in the chemo-refractory setting opened the way to the concepts of treatment sequencing in mCRC. However, the impact of later line options in the therapeutic route of metastatic colorectal cancer (mCRC) patients and the attrition rate across subsequent lines of therapy are not well established. METHODS: We performed a pooled analysis of treatments administered after the 2nd disease progression in 1187 mCRC patients enrolled in the randomized phase III TRIBE and TRIBE2 studies, where upfront FOLFOXIRI/bev was compared with FOLFOX or FOLFIRI/bev. Per each line, we assessed the attrition rate, treatment choices and clinical outcomes. RESULTS: 625 (53%), 326 (27%) and 136 (11%) patients received a systemic treatment after the 2nd, 3rd and 4th disease progression, respectively. PFS and objective response rate decreased along each line. RAS/BRAF wild-type patients received more likely a 3rd line (75%) compared with RAS (66%, p = 0.005) and BRAF (66%, p = 0.11) mutants. In 3rd line, 67% of RAS/BRAF wild-type patients received anti-EGFRs, achieving longer PFS with respect to other therapies (6.4 vs 3.9 months, p = 0.02). A trend towards longer 3rd line OS was observed in TRIBE patients (9.9 vs 7.2 months, p = 0.05). CONCLUSIONS: A relevant attrition rate across subsequent lines of therapy is evident, and more pronounced in RAS and BRAF mutated patients, thus highlighting the relevance of the choice of the upfront treatment. The efficacy of anti-EGFR agents among RAS/BRAF wild-type patients unexposed to anti-EGFRs is higher than other options. The reintroduction of chemotherapy remains frequent in clinical practice. TRIAL REGISTRATION: Clinicaltrials. gov Identifiers NCT00719797, NCT02339116.
引用
- Rossini D, Germani MM, Lonardi S, et al. Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies. Eur J Cancer. 2022. PMID: 35594613. doi:10.1016/j.ejca.2022.04.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。